Ardelyx Inc. (41X)
Summary
41X Chart
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Ardelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability.
Ardelyx: Low Price, But High Implied Valuation
Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside.
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx Inc. (41X) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ardelyx Inc. ever had a stock split?
Ardelyx Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael G. Raab CEO | XBER Exchange | US0396971071 ISIN |
| US Country | 489 Employees | - Last Dividend | - Last Split | 19 Jun 2014 IPO Date |
Overview
Ardelyx, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines targeting gastrointestinal and cardiorenal therapeutic areas. The company's efforts are primarily focused on addressing the needs of patients in the United States and internationally. Ardelyx was originally established as Nteryx, Inc. and underwent a name change to Ardelyx, Inc. in June 2008. With its foundation in 2007 and headquarters situated in Waltham, Massachusetts, Ardelyx is at the forefront of developing potential treatments for various conditions related to the gastrointestinal tract and renal-cardiac health.
Products and Services
Ardelyx, Inc. is engaged in the development of a range of therapeutic products, including:
- Tenapanor: This is the lead product candidate of Ardelyx, aiming at treating patients suffering from irritable bowel syndrome with constipation (IBS-C). Tenapanor shows promise in alleviating symptoms associated with IBS-C, demonstrating Ardelyx's focus on addressing gastrointestinal disorders.
- XPHOZAH (Phase III): Currently in Phase III clinical trial, XPHOZAH is developed to reduce serum phosphorus in adults suffering from chronic kidney disease (CKD) on dialysis, or those with hyperphosphatemia. This treatment is indicative of Ardelyx's dedication to advancing care in the cardiorenal therapeutic area.
- RDX013: This potassium secretagogue is designed for the treatment of elevated serum potassium, or hyperkalemia, a frequent complication among patients with kidney and/or heart failure. RDX013 embodies the company's efforts to tackle key issues in cardiorenal health through innovative therapeutic solutions.
- RDX020: Targeted towards adult patients with metabolic acidosis, a serious electrolyte disorder, RDX020 is another testament to Ardelyx's commitment to addressing complex cardiorenal conditions.
In addition to developing these pioneering treatments, Ardelyx has forged strategic agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. These partnerships are focused on the development and commercialization of tenapanor in their respective territories, further illustrating Ardelyx's efforts to bring its innovative solutions to a global market.
